Jakafi® (ruxolitinib) is now FDA approved to treat chronic graft-versus-host disease (cGVHD) in patients who are at least 12 years old and have failed treatment with one or two lines of systemic therapy.

• Graft-versus host disease occurs when stem cells from donated bone marrow attack healthy cells in the recipient’s body. It can be acute (occurring within 100 days of the transplant) or chronic (occurring 100 days or more after the transplant).
• In addition to treating cGVHD, Jakafi is also indicated to treat acute graft-versus-host disease, polycythemia vera (a type of blood cancer), and intermediate or high-risk myelofibrosis (a type of bone marrow cancer).
• The recommended starting dose for the new indication is 10mg taken by mouth twice daily. The daily dose may need to be reduced based on patient response and other clinical
• Jakafi, which is made by Incyte, first received FDA approval in